We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Blood Vessels Grown in Lab to Treat Heart Disease

By LabMedica International staff writers
Posted on 02 Sep 2009
Although open-heart surgery is a frequent treatment for heart disease, it remains a very dangerous procedure. More...
New research from Israel has shown the potential for an injected protein to regrow blood vessels in the human heart--eliminating the need for risky surgery altogether.

In heart disease, either blood vessels are clogged or they die off, starving the heart of oxygen and leaving it highly susceptible to a cardiac attack. Dr. Britta Hardy and her research partner Prof. Alexander Battler, from Tel Aviv University's Sackler School of Medicine (Israel) have developed a protein-based injection that when delivered to muscles in the body, spurs the growth of tiny blood vessels. These new vessels in the heart could give millions of people worldwide a new lease on life.

An article on the procedure was published in the August 10, 2009, issue of the journal Biochemical Pharmacology. "The biotechnology behind our human-based protein therapy is very complicated, but the goal is simple and the solution is straightforward,” stated Dr. Hardy. "We intend to inject our drug locally to heal any oxygen-starved tissue. So far, in animal models, we have seen no side effects and no inflammation following our injection of the drug into the legs. The growth of new blood vessels happens within a few weeks, showing improved blood circulation.”

The protein solution can also be added as a coating to a stent. Currently, the implantation of a stent is accompanied by a high risk for blood clots, which necessitates the use of blood thinners. "We could coat a stent with our peptide, attracting endothelial stem cells to form a film on the surface of the stent,” Dr. Hardy explained. "These endothelial cells on the stent would eliminate the need for taking the blood thinners that prevent blood clots from forming.”

If investment goals are met, Dr. Hardy anticipates toxicity studies and phase I trials could be complete within two years. The research began with the hope of preventing leg amputations, positing that proteins from the human body could be used to trigger the growth of new blood vessels. Dr. Hardy started by studying a library of peptides and testing them in the laboratory. Dr. Hardy was able to validate initial results. She then took some of the isolated and synthesized peptides and tested them in diabetic mice whose legs were in the process of dying.

Although diabetes is known to decrease blood circulation, Dr. Hardy found that her therapy reversed the decrease. "Within a short time we saw the formation of capillaries and tiny blood vessels. After three weeks, they had grown and merged together with the rest of the circulatory system,” she commented. In mice with limited blood circulation, she was able to completely restore blood vessels and save their legs. The next step is examining the applicability of the research to cardiac patients.

A new therapy could be commercially available soon. Unlike studies for other drugs, clinical results with the blood vessels are nearly immediate. "It's pretty obvious if there is regrowth or not. Our technology promises to regrow blood vessels like a net, and a heart that grows more blood vessels becomes stronger. It's now imaginable that, in the distant future, peptide injections may be able to replace bypass surgeries,” Dr. Hardy concluded.

Related Links:

Tel Aviv University's Sackler School of Medicine




Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
Multichem ID-B
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.